ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002
August 12, 2021Lynk Pharmaceuticals Co., Ltd., an innovative drug development company, announced today that it has administered its triple-kinase inhibitor LNK01002 to the first patient in a phase I clinical trial. -
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003
June 25, 2021Lynk Pharmaceuticals Co., Ltd. announced today that its new Class I innovative drug LNK01003, has been approved by National Medical Products Administration (NMPA) for clinical trials of inflammatory bowel disease (IBD).
Pharma Sources Insight January 2025
